We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
After nearly 10 years at the CEO post for GlaxoSmithKline, Andrew Witty is handing over the reins to a company that has been reshaped with a vaccines focus. And during Witty’s final full year at the drugmaker, that business segment outgrew each of GSK’s o